Personalized virotherapy in cancer

Cafferata, Eduardo G.; Podhajcer, Osvaldo L.

doi:10.18632/aging.100750

Cited by 1 publication

(2 citation statements)

References 8 publications

(9 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Each group was composed of at least eight animals and tumor growth was monitored and measured for every 5 days with a Vernier caliper. Tumor volume (V) was calculated according to the formula: V (mm 3 ) =1/2× length (mm) × width (mm) 2 . Once the subcutaneous tumors reached ~100–150 mm 3 , the nude mice were divided into four groups (8 mice in each group) randomly.…”

Section: Methodsmentioning

confidence: 99%

“…Cancer virotherapy is a tumor-specific therapeutic strategy, in which viruses are engineered to preferentially replicate in tumor cells and destroy it by lysis, either through targeted alterations in the cancer cells, such as p53 mutation, viral deletion, tissue-specific transcriptional control, or tumor-specific receptors. 2 Among available virotherapies, conditionally replicating adenovirus is attractive because of its several attributes, including lytic replication, efficient genome transfer, and excellent patient safety in clinical trials. 3 , 4 In our previous study, we have developed a cancer-targeting gene virotherapy strategy 5 and generated a novel E1B55K gene deleted oncolytic adenovirus ZD55-MnSOD, harboring manganese superoxide dismutase (MnSOD) gene.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Synergistic suppression effect on tumor growth of ovarian cancer by combining cisplatin with a manganese superoxide dismutase-armed oncolytic adenovirus

Wang

Shu²,

Chen

et al. 2016

OTT

View full text Add to dashboard Buy / Rent full text

Gene therapy on the basis of oncolytic adenovirus is a novel approach for human cancer therapeutics. We aim to investigate whether it will synergistically reinforce their antiovarian cancer activities when the combined use of ZD55-manganese superoxide dismutase (MnSOD) and cisplatin was performed. The experiments in vitro showed that ZD55-MnSOD enhances cisplatin-induced apoptosis and causes remarkable ovarian cancer cell death. Apoptosis induction by treatment with ZD55-MnSOD and/or cisplatin was detected in SKOV-3 by apoptotic cell staining, flow cytometry, and western blot analysis. In addition, the cytotoxicity caused by ZD55-MnSOD to normal cells was examined by the 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide assay and western blot analysis. Animal experiment further confirmed that combination of ZD55-MnSOD and cisplatin achieved significant inhibition of SKOV-3 ovarian tumor xenografted growth. In summary, we have demonstrated that ZD55-MnSOD can sensitize human ovarian cancer cells to cisplatin-induced cell death and apoptosis in vitro and in vivo. These findings indicate that the combined treatment with ZD55-MnSOD and cisplatin could represent a rational approach for antiovarian cancer therapy.

show abstract

Section: Methodsmentioning

confidence: 99%